Literature DB >> 33511140

Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China.

Yansong Lin1, Xiaorong Gong2, Xin Li3, Congxiang Shao1, Tingfeng Wu1, Minrui Li1, Fuxi Li1, Qianqian Ma1, Junzhao Ye1, Bihui Zhong1.   

Abstract

Background: The clinical burden and natural history of non-alcoholic fatty liver disease (NAFLD) vary globally. We aimed to investigate NAFLD-related mortality profiles in hospitalized patients in southern China.
Methods: A multicenter retrospective investigation with a 10-year study period (2009-2018) analyzed 10,071 deaths during hospitalization (NAFLD: 2,015; other liver diseases: 1,140; without liver diseases: 6,916) was performed using a multiple cause of death analysis. Medical histories and biochemistry and imaging findings were extracted from the electronic medical record system. The underlying causes of death were classified by 10th Revision of the International Classification of Diseases (ICD-10) codes.
Results: The distribution of death causes in patients with NAFLD has stabilized over time, with cardio- and cerebral vascular disease (CVD) ranked first (35.6%), followed by extrahepatic malignancies (22.6%), infection (11.0%), kidney disease (7.5%), liver-related diseases (5.2%), respiratory diseases (3.9%), digestive diseases (3.5%), endocrine diseases (3.5%), and other diseases (7.2%). NAFLD patients had more deaths attributable to CVD, extrahepatic malignancies, liver-related diseases (all P < 0.001) and multiorgan failure than the deceased controls. The severity of steatosis was independently associated with these relationships (liver-related diseases: OR = 1.37, 95% CI: 1.20-1.59, cardio- and cerebrovascular diseases: OR = 1.23, 95% CI: 1.19-1.31, infectious diseases: OR = 1.14, 95% CI: 1.04-1.26, and renal diseases: OR = 1.21, 95% CI: 1.02-1.47, all P < 0.05) after adjustment for sex, body mass index (BMI), fasting blood glucose, low-density lipoprotein cholesterol, uric acid, metabolic syndromes and fibrosis index based on the 4 factors. Conclusion : NAFLD patients had higher proportions of death due to underlying CVD and liver-related diseases than the general population in China; these proportions positively correlated with steatosis degree.
Copyright © 2021 Lin, Gong, Li, Shao, Wu, Li, Li, Ma, Ye and Zhong.

Entities:  

Keywords:  cause of death; multiorgan failure; non-alcoholic fatty liver disease; real world study; steatosis degree

Year:  2021        PMID: 33511140      PMCID: PMC7835127          DOI: 10.3389/fmed.2020.584396

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  34 in total

1.  The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.

Authors:  Alina M Allen; Stephen B Hicks; Kristin C Mara; Joseph J Larson; Terry M Therneau
Journal:  J Hepatol       Date:  2019-08-27       Impact factor: 25.083

2.  Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities.

Authors:  Kristina Önnerhag; Karl Dreja; Peter M Nilsson; Stefan Lindgren
Journal:  Clin Res Hepatol Gastroenterol       Date:  2019-03-01       Impact factor: 2.947

3.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

4.  Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.

Authors:  Donghee Kim; Adeyinka C Adejumo; Eric R Yoo; Umair Iqbal; Andrew A Li; Edward A Pham; George Cholankeril; Jeffrey S Glenn; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2019-06-25       Impact factor: 22.682

5.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

6.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

7.  Liver fat scores predict liver disease mortality in the United States population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Aliment Pharmacol Ther       Date:  2018-09-18       Impact factor: 8.171

8.  Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia.

Authors:  W B Nseir; J M Mograbi; A E Amara; O H Abu Elheja; M N Mahamid
Journal:  QJM       Date:  2019-02-01

9.  Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Di Sun; Jing-Lu Jin; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Ying Gao; Qiu-Ting Dong; Xi Zhao; Sha Li; Yan Zhang; Geng Liu; Jian-Jun Li
Journal:  Clin Transl Gastroenterol       Date:  2019-02       Impact factor: 4.488

10.  The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study.

Authors:  Young-Kyu Kim; Oh-Sung Kwon; Kyu Hee Her
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

View more
  5 in total

Review 1.  Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.

Authors:  Gashaw Hassen; Abhishek Singh; Gizeshwork Belete; Nidhi Jain; Ivonne De la Hoz; Genesis P Camacho-Leon; Nitsuh K Dargie; Keila G Carrera; Tadesse Alemu; Sharan Jhaveri; Nebiyou Solomon
Journal:  Cureus       Date:  2022-05-30

2.  Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study.

Authors:  Xianhua Liao; Qianqian Ma; Tingfeng Wu; Congxiang Shao; Yansong Lin; Yanhong Sun; Shiting Feng; Wei Wang; Junzhao Ye; Bihui Zhong
Journal:  Diabetes Metab Syndr Obes       Date:  2022-04-18       Impact factor: 3.249

Review 3.  Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Ling Luo; Qianqian Ma; Limin Lin; Hao Wang; Junzhao Ye; Bihui Zhong
Journal:  Dis Markers       Date:  2022-08-12       Impact factor: 3.464

4.  The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population.

Authors:  Haofei Hu; Yong Han; Changchun Cao; Yongcheng He
Journal:  J Transl Med       Date:  2022-09-05       Impact factor: 8.440

5.  Greater Muscular Strength Is Associated with a Lower Risk of Pulmonary Dysfunction in Individuals with Non-Alcoholic Fatty Liver Disease.

Authors:  Jinkyung Cho; Bruce D Johnson; Kymberly D Watt; Chul-Ho Kim
Journal:  J Clin Med       Date:  2022-07-17       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.